Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy

Table 2: Rates of Drug Resistance Following Virologic Breakthrough on NNRTI-Based Therapy

Mutations	With Baseline 135 Mutation	Without Baseline 135 Mutation	p-Value
NRTIs L74V M184I/V TAMs 1 Mutation >1 Mutation NNRTIs L100I K103N V106M V108I Y181C Y188C G190A 1 Mutation >1 Mutation No resistance mutations	4/14 (29%) 2 (14%) 3 (21%) 2 (14%) 1 (7%) 3 (21%) 10/14 (71%) 0 (0%) 6 (43%) 0 (0%) 1 (7%) 3 (21%) 0 (0%) 2 (14%) 8 (57%) 2 (14%) 4/14 (29%)	12/22 (55%) 3 (14%) 12 (55%) 1 (5%) 7 (32%) 5 (23%) 16/22 (73%) 1 (5%) 10 (45%) 1 (5%) 2 (9%) 9 (41%) 1 (5%) 7 (32%) 4 (18%) 12 (55%) 5/22 (23%)	0.18 0.99 0.08 0.55 0.12 0.99 0.99 0.99 0.99 0.99 0.99 0.29 0.99 0.43 0.029 0.033 0.71

Note: NNRTI indicates non-nucleoside reverse transcriptase inhibitor, NRTI indicates nucleoside reverse transcriptase inhibitor, TAM indicates thymidine analogue mutation.